NCT02764554
Completed
Not Applicable
Post-Marketing Surveillance of Lenvima in Korean Patients
ConditionsDifferentiated Thyroid Carcinoma (DTC)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Differentiated Thyroid Carcinoma (DTC)
- Sponsor
- Eisai Korea Inc.
- Enrollment
- 132
- Locations
- 32
- Primary Endpoint
- Number of Participants with Adverse Events, Serious Adverse Events, and Adverse Drug Reactions
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Investigators will refer to approved indications and contraindications regarding exclusion criteria
Outcomes
Primary Outcomes
Number of Participants with Adverse Events, Serious Adverse Events, and Adverse Drug Reactions
Time Frame: Up to 1 year
Study Sites (32)
Loading locations...
Similar Trials
Completed
Not Applicable
A Study of Fycompa (Perampanel) in Korean ParticipantsEpilepsyNCT02722590Eisai Korea Inc.3,692
Completed
Phase 4
Post Marketing Surveillance for ADACEL™ in South KoreaDiphtheriaTetanusPertussisNCT01137435Sanofi Pasteur, a Sanofi Company659
Completed
Not Applicable
Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)Hepatitis ANCT01838070Sanofi Pasteur, a Sanofi Company614
Withdrawn
Not Applicable
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and NeckNeoplasms, Squamous CellNCT01075841Merck KGaA, Darmstadt, Germany
Recruiting
Not Applicable
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea PatientsHyperphosphatemiaNCT06186934Kyowa Kirin Korea Co., Ltd.600